MARKET

NVO

NVO

Novo-Nordisk A/S
NYSE
125.79
-0.37
-0.29%
After Hours: 126.32 +0.53 +0.42% 19:59 04/25 EDT
OPEN
123.69
PREV CLOSE
126.16
HIGH
125.85
LOW
123.21
VOLUME
3.43M
TURNOVER
0
52 WEEK HIGH
138.28
52 WEEK LOW
74.66
MARKET CAP
561.19B
P/E (TTM)
45.63
1D
5D
1M
3M
1Y
5Y
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
NASDAQ · 20h ago
West Pharma posts beat-and-raise quarter aided by strong demand for injectables
West Pharma posts beat-and-raise quarter aided by strong demand for injectables. The company posted a first-quarter profit of $1.56 per share. West Pharmaceutical Services raised its annual profit forecast to $7.88 per share for 2024. Company expects sales growth to ramp up as the year progresses.
Reuters · 22h ago
Novo Nordisk Updates Corporate Governance Structure
TipRanks · 22h ago
Novo Nordisk Executes Share Capital Reduction
TipRanks · 22h ago
Scholz promises support for pharma sector in Germany as Merck invests
German Chancellor Olaf Scholz promises support for pharma sector in Germany as Merck invests. Merck is investing 1.5 billion euros in Germany. The drugmaker plans to use its life sciences Advanced Research Centre in Darmstadt. Germany has sought to improve conditions for the pharma and biotech sector.
Reuters · 22h ago
Plaintiffs' lawyers chosen to lead Ozempic litigation
Plaintiffs' lawyers chosen to lead Ozempic litigation. Lawsuits allege companies failed to warn of harsh side effects associated with diabetes and weight loss drugs. A judge appointed eight plaintiffs' lawyers to leadership roles in federal mass tort litigation. The companies have said the claims are meritless.
Reuters · 1d ago
Novo Nordisk comes under Senate probe over pricing for weight loss drugs
Danish drugmaker Novo Nordisk comes under Senate probe over pricing for weight loss drugs. Sen. Bernie Sanders says the company charges 'outrageously high prices' for the popular drug semaglutide in the U.S. The Senate committee wants to know how the company prices the drug.
Seeking Alpha · 1d ago
US Senate committee investigates pricing of Novo's Ozempic and Wegovy
US Senate committee investigates pricing of Novo's Ozempic and Wegovy diabetes and weight loss drugs. Committee seeks more information on U.S. Prices for the two drugs, which are higher than the prices in other countries. Novo Nordisk says it is committed to working with policymakers.
Reuters · 1d ago
More
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Webull offers Novo Nordisk A/S (ADR) stock information, including NYSE: NVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVO stock methods without spending real money on the virtual paper trading platform.